MX2017000094A - PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. - Google Patents
PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.Info
- Publication number
- MX2017000094A MX2017000094A MX2017000094A MX2017000094A MX2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- acid sequences
- mutein
- amyloid
- products based
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021308P | 2014-07-07 | 2014-07-07 | |
| PCT/EP2015/065362 WO2016005328A2 (en) | 2014-07-07 | 2015-07-06 | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017000094A true MX2017000094A (es) | 2017-04-27 |
Family
ID=53525183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000094A MX2017000094A (es) | 2014-07-07 | 2015-07-06 | PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160000891A1 (enExample) |
| EP (1) | EP3166969A2 (enExample) |
| JP (3) | JP2017532289A (enExample) |
| CN (1) | CN107074924A (enExample) |
| AU (2) | AU2015286824A1 (enExample) |
| CA (1) | CA2954031A1 (enExample) |
| IL (1) | IL249925B (enExample) |
| MX (1) | MX2017000094A (enExample) |
| RU (1) | RU2750268C2 (enExample) |
| SG (1) | SG11201700071WA (enExample) |
| WO (1) | WO2016005328A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| MX336196B (es) * | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| CN107074924A (zh) * | 2014-07-07 | 2017-08-18 | 艾伯维德国有限责任两合公司 | 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 |
| WO2018047792A1 (ja) * | 2016-09-06 | 2018-03-15 | 富士レビオ株式会社 | サイログロブリンの測定方法及び測定試薬 |
| US11802867B2 (en) | 2016-09-13 | 2023-10-31 | Fujirebio Inc. | Cardiac troponin assay method and assay reagent |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN110412294B9 (zh) * | 2019-08-07 | 2023-05-26 | 深圳市新产业生物医学工程股份有限公司 | 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN112851786B (zh) * | 2019-11-12 | 2022-11-15 | 深圳市新产业生物医学工程股份有限公司 | 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒 |
| CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
| EP4286405A4 (en) * | 2021-01-28 | 2025-03-19 | Abrain | GENE THERAPY FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP4230645A1 (en) * | 2022-02-22 | 2023-08-23 | Technische Universität München | Peptidic inhibitors of amyloid self- and cross-assembly |
| CN117586370A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 强毒性淀粉样蛋白寡聚体及其用途 |
| CN117700525B (zh) * | 2024-02-05 | 2024-06-18 | 上海良润生物医药科技有限公司 | 一种多肽改造体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| PT1954718E (pt) * | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| CN102203124A (zh) * | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 |
| MX336196B (es) * | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP3533803B1 (en) * | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| CN107074924A (zh) * | 2014-07-07 | 2017-08-18 | 艾伯维德国有限责任两合公司 | 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 |
-
2015
- 2015-07-06 CN CN201580047718.9A patent/CN107074924A/zh active Pending
- 2015-07-06 US US14/792,500 patent/US20160000891A1/en not_active Abandoned
- 2015-07-06 EP EP15735674.2A patent/EP3166969A2/en not_active Withdrawn
- 2015-07-06 RU RU2017103527A patent/RU2750268C2/ru active
- 2015-07-06 MX MX2017000094A patent/MX2017000094A/es unknown
- 2015-07-06 CA CA2954031A patent/CA2954031A1/en active Pending
- 2015-07-06 AU AU2015286824A patent/AU2015286824A1/en not_active Abandoned
- 2015-07-06 JP JP2017500952A patent/JP2017532289A/ja active Pending
- 2015-07-06 SG SG11201700071WA patent/SG11201700071WA/en unknown
- 2015-07-06 WO PCT/EP2015/065362 patent/WO2016005328A2/en not_active Ceased
-
2017
- 2017-01-04 IL IL249925A patent/IL249925B/en unknown
-
2020
- 2020-09-18 JP JP2020156999A patent/JP2021001203A/ja active Pending
-
2021
- 2021-01-29 AU AU2021200575A patent/AU2021200575A1/en not_active Abandoned
-
2022
- 2022-10-27 US US18/050,314 patent/US20240075114A1/en active Pending
- 2022-12-01 JP JP2022192713A patent/JP2023036606A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015286824A1 (en) | 2017-02-09 |
| IL249925A0 (en) | 2017-03-30 |
| RU2017103527A (ru) | 2018-08-07 |
| JP2017532289A (ja) | 2017-11-02 |
| WO2016005328A2 (en) | 2016-01-14 |
| US20160000891A1 (en) | 2016-01-07 |
| JP2021001203A (ja) | 2021-01-07 |
| BR112017000428A2 (pt) | 2017-10-31 |
| CA2954031A1 (en) | 2016-01-14 |
| RU2750268C2 (ru) | 2021-06-25 |
| WO2016005328A3 (en) | 2016-05-26 |
| US20240075114A1 (en) | 2024-03-07 |
| SG11201700071WA (en) | 2017-02-27 |
| JP2023036606A (ja) | 2023-03-14 |
| CN107074924A (zh) | 2017-08-18 |
| IL249925B (en) | 2021-09-30 |
| RU2017103527A3 (enExample) | 2019-02-19 |
| EP3166969A2 (en) | 2017-05-17 |
| AU2021200575A1 (en) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017000094A (es) | PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. | |
| ZA201708692B (en) | Antibacterial compounds | |
| MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
| MD4801B1 (ro) | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice | |
| GB2541571A (en) | Pharmaceutical compositions | |
| EA201990043A1 (ru) | Антибактериальные соединения | |
| MX2017001971A (es) | Composiciones antimetanogenicas y sus usos. | |
| WO2016149501A3 (en) | Modified therapeutic agents and compositions thereof | |
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| MX373912B (es) | Terapias antibioticas peptidicas derivadas del bufalo de agua | |
| WO2017042577A8 (en) | Novel therapy | |
| WO2016135456A3 (en) | A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| WO2016073493A3 (en) | Antifibrinolytic compounds | |
| PH12017501943B1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis | |
| PH12017501918A1 (en) | Multi-peptide composition | |
| HK1240079A1 (en) | Method for treating hyperhidrosis | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |